Research progress on mechanisms and therapeutic drugs of hypoxic pulmonary hypertension

Author: Jian-Mei WANG ¹ ; Tian-Yi YUAN ¹ ; Guan-Hua DU ¹ ; Jian-Mei WANG ² ; Li GAO ² ; Xue-Mei QIN ²
Author Information

1. Beijing Key Lab of Drug Target Identification and Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College
2. Modern Research Center for Traditional Chinese Medicine, Shanxi University
Publication Type:Journal Article
Keywords: clinical medi¬cines; drug:trgste; experimental dnrgs; hypoxic pulmonary hypertension; pulmonary vascular remodeling; pulmonary vaso¬constriction
From: Chinese Pharmacological Bulletin 2022;38(9):1281-1288
CountryChina
Language:Chinese
Abstract: Hypoxic pulmonary hypertension ( HPH) is a complex mechanism of HPH is complex, and it has a high mortality rate cardiopulmonary disease eaused by hypoxia.The pathological of disability.Clinically the diug of treatment for HPH is unspe-cialized, mainly relying on traditional vasomotor dnrgs, inclu¬ding prostaglandin 12 receptor agonists, endothelin receptor an¬tagonists and phosphodiesterase-5 inhibitors, but their efficacy cannot be achieved.To meet the clinical need, it is of great sig¬nificance to develop targeted anti-HPH dnigs.To provide ideas for the discovery of HPH treatment drugs, the pathophysiological mechanism of HPH and the current status of dmg development are reviewed in the paper.